Skip to content
Industry
This is research, not advice. We’re not SEBI-registered.

Alkermes share price today

Alkermes plc · ALKS · Healthcare · Drug Manufacturers - Specialty & Generic · price as of the 4 November 2026 close, updated every trading day · results updated weekly · All US stock lists

Alkermes share price: $45.89 at the close on 4 November 2026, +39.5% in a year.

Getting worseBusiness trend from the last 12 quarters
$45.89Price +39.5% in a year
115.6×P/E higher than 93% of the last 3.3 years
$496 MRevenue (Jun 2026) +27.0% on a year ago
$501 KProfit (Jun 2026) −99.4% on a year ago
15.5%Operating margin −8.3 points on a year ago
13%ROE FY25
−0.3%ROIC against a 4.6% cost of capital: −4.9 points

Alkermes plc's share price has risen faster than its earnings: +39.5% in a year, against −34.1% for earnings per share.

The main question: the share price moved +39.5% in a year while yearly earnings per share moved −34.1%. The difference came from the market paying a higher multiple.

The price has been rising for 26 weeks, and the P/E is higher than 93% of its own last 3.3 years. Over the last four quarters, results have been deteriorating, with profit −99.4% on a year earlier, and 141% of the last 3 years' profit came in as cash. What will decide it: whether earnings grow into a price that has already moved.

What is the Alkermes share price today?

Alkermes plc's share price was $45.89 at the close on 4 November 2026. It has been rising for 26 weeks. That is 12.8% above its average price over the last 200 trading days. In the last 52 weeks it traded between $28 and $55, and at that close it sat 66% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Alkermes plc is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 8 weeks running.

1Y

Nov 2026: $45.89, 12.8% above its 200-day average. The price has been rising for 26 weeks.

  • Price $45.89
  • 50-day avg $43.86
  • 200-day avg $40.68
Nov 2026: $45.89, 12.8% above its 200-day average. The price has been rising for 26 weeks.
WeekPrice50-day avg200-day avg
31 Oct 2025$30.70$29.60$30.31
7 Nov 2025$32.89$29.80$30.34
14 Nov 2025$29.04$30.02$30.34
21 Nov 2025$28.61$30.14$30.28
28 Nov 2025$29.58$30.26$30.22
5 Dec 2025$29.52$30.43$30.06
12 Dec 2025$28.50$30.33$29.90
19 Dec 2025$28.45$30.02$29.74
26 Dec 2025$28.49$29.76$29.62
2 Jan 2026$28.26$29.53$29.50
9 Jan 2026$29.66$29.40$29.37
16 Jan 2026$31.63$29.38$29.30
23 Jan 2026$33.61$29.47$29.35
30 Jan 2026$33.89$29.77$29.50
6 Feb 2026$34.91$30.35$29.68
13 Feb 2026$33.16$30.85$29.84
20 Feb 2026$31.91$31.07$29.87
27 Feb 2026$30.10$31.36$29.90
6 Mar 2026$28.63$31.45$29.85
13 Mar 2026$27.76$31.41$29.79
20 Mar 2026$28.15$31.35$29.72
27 Mar 2026$29.39$31.28$29.66
2 Apr 2026$34.84$31.41$29.73
10 Apr 2026$33.36$31.46$29.85
17 Apr 2026$34.53$31.39$29.97
24 Apr 2026$33.31$31.31$30.08
1 May 2026$33.38$31.41$30.18
8 May 2026$34.99$31.75$30.37
15 May 2026$37.48$32.58$30.64
22 May 2026$36.80$33.47$30.90
29 May 2026$42.19$34.41$31.15
5 Jun 2026$42.80$35.82$31.50
12 Jun 2026$44.28$37.02$31.87
18 Jun 2026$44.99$37.84$32.18
26 Jun 2026$55.08$39.51$32.71
2 Jul 2026$54.58$41.01$33.23
10 Jul 2026$51.94$43.04$33.88
17 Jul 2026$52.72$44.82$34.49
24 Jul 2026$52.89$46.49$35.03
31 Jul 2026$48.99$47.73$35.50
7 Aug 2026$49.17$48.93$35.95
14 Aug 2026$49.06$49.71$36.43
21 Aug 2026$48.33$50.29$36.88
28 Aug 2026$47.41$50.72$37.31
4 Sep 2026$46.10$50.57$37.71
11 Sep 2026$45.97$49.99$38.05
18 Sep 2026$43.39$49.09$38.47
25 Sep 2026$40.85$48.13$38.79
2 Oct 2026$41.75$46.95$39.09
9 Oct 2026$40.61$45.99$39.42
16 Oct 2026$41.22$45.08$39.72
23 Oct 2026$43.63$44.49$40.10
30 Oct 2026$45.34$44.06$40.48
4 Nov 2026$45.89$43.86$40.68
Weekly closing price ($) with its 50-day and 200-day averages. The strip under the chart shows the phase: tan sideways, green rising, yellow stalling near a high, orange falling. 1-year window.

3Y

Nov 2026: $45.89, 12.8% above its 200-day average. The price has been rising for 26 weeks.

  • Price $45.89
  • 50-day avg $43.86
  • 200-day avg $40.68
Nov 2026: $45.89, 12.8% above its 200-day average. The price has been rising for 26 weeks.
WeekPrice50-day avg200-day avg
3 Nov 2023$24.79$27.77$28.76
10 Nov 2023$23.80$27.44$28.68
17 Nov 2023$24.24$26.91$28.56
24 Nov 2023$24.39$26.45$28.51
1 Dec 2023$24.29$25.86$28.42
8 Dec 2023$25.86$25.62$28.38
15 Dec 2023$27.42$25.50$28.38
22 Dec 2023$27.92$25.43$28.39
29 Dec 2023$27.74$25.45$28.41
5 Jan 2024$28.56$25.67$28.46
12 Jan 2024$28.20$26.12$28.51
19 Jan 2024$27.90$26.36$28.50
26 Jan 2024$27.74$26.73$28.48
2 Feb 2024$26.74$27.07$28.43
9 Feb 2024$27.32$27.35$28.36
16 Feb 2024$32.18$27.81$28.39
23 Feb 2024$29.57$28.08$28.39
1 Mar 2024$30.24$28.36$28.36
8 Mar 2024$29.25$28.54$28.33
15 Mar 2024$28.75$28.59$28.32
22 Mar 2024$27.29$28.46$28.26
28 Mar 2024$27.07$28.39$28.18
5 Apr 2024$26.12$28.22$28.04
12 Apr 2024$24.42$28.02$27.86
19 Apr 2024$23.85$27.73$27.68
26 Apr 2024$24.68$27.41$27.54
3 May 2024$24.05$26.78$27.37
10 May 2024$24.05$26.22$27.20
17 May 2024$24.15$25.69$27.08
24 May 2024$24.02$25.23$26.99
31 May 2024$23.40$24.87$26.89
7 Jun 2024$23.91$24.56$26.76
14 Jun 2024$24.50$24.36$26.69
21 Jun 2024$24.95$24.25$26.60
28 Jun 2024$24.10$24.26$26.47
5 Jul 2024$24.29$24.28$26.36
12 Jul 2024$23.57$24.19$26.22
19 Jul 2024$24.83$24.21$26.12
26 Jul 2024$27.88$24.43$26.07
2 Aug 2024$27.72$24.75$26.06
9 Aug 2024$26.07$25.05$26.07
16 Aug 2024$27.25$25.34$26.13
23 Aug 2024$27.95$25.72$26.21
30 Aug 2024$28.45$26.07$26.31
6 Sep 2024$26.86$26.31$26.38
13 Sep 2024$27.66$26.57$26.45
20 Sep 2024$28.55$27.00$26.54
27 Sep 2024$27.53$27.32$26.57
4 Oct 2024$28.97$27.60$26.61
11 Oct 2024$28.91$27.60$26.60
18 Oct 2024$28.27$27.71$26.61
25 Oct 2024$26.09$27.81$26.57
1 Nov 2024$26.47$27.64$26.53
8 Nov 2024$28.86$27.66$26.54
15 Nov 2024$28.19$27.79$26.57
22 Nov 2024$28.78$27.88$26.60
29 Nov 2024$29.02$27.99$26.63
6 Dec 2024$31.46$28.29$26.63
13 Dec 2024$30.51$28.53$26.66
20 Dec 2024$29.71$28.80$26.67
27 Dec 2024$29.55$28.89$26.69
3 Jan 2025$29.04$28.94$26.70
10 Jan 2025$28.08$29.07$26.72
17 Jan 2025$29.47$29.34$26.77
24 Jan 2025$31.19$29.50$26.87
31 Jan 2025$31.53$29.75$27.02
7 Feb 2025$31.57$30.09$27.21
14 Feb 2025$35.89$30.54$27.44
21 Feb 2025$35.32$30.92$27.67
28 Feb 2025$34.33$31.32$27.93
7 Mar 2025$34.35$31.77$28.19
14 Mar 2025$34.03$32.24$28.44
21 Mar 2025$34.60$32.80$28.71
28 Mar 2025$33.21$33.33$28.95
4 Apr 2025$30.06$33.50$29.13
11 Apr 2025$27.00$33.16$29.22
17 Apr 2025$27.00$32.85$29.28
25 Apr 2025$27.84$32.39$29.35
2 May 2025$31.78$31.76$29.50
9 May 2025$30.13$31.33$29.65
16 May 2025$31.42$30.96$29.74
23 May 2025$29.35$30.60$29.81
30 May 2025$30.61$30.27$29.89
6 Jun 2025$31.71$29.99$30.00
13 Jun 2025$29.83$29.77$30.07
20 Jun 2025$29.09$29.74$30.09
27 Jun 2025$28.81$29.88$30.13
3 Jul 2025$28.85$30.02$30.17
11 Jul 2025$30.28$30.22$30.21
18 Jul 2025$29.22$30.09$30.26
25 Jul 2025$26.13$29.70$30.21
1 Aug 2025$26.55$29.26$30.20
8 Aug 2025$26.71$28.93$30.15
15 Aug 2025$29.05$28.62$30.17
22 Aug 2025$29.75$28.40$30.23
29 Aug 2025$28.97$28.32$30.25
5 Sep 2025$29.94$28.35$30.26
12 Sep 2025$26.97$28.22$30.25
19 Sep 2025$27.79$28.03$30.21
26 Sep 2025$27.89$27.85$30.14
3 Oct 2025$31.06$28.15$30.13
10 Oct 2025$31.21$28.60$30.16
17 Oct 2025$30.26$29.09$30.21
24 Oct 2025$29.80$29.40$30.26
31 Oct 2025$30.70$29.60$30.31
7 Nov 2025$32.89$29.80$30.34
14 Nov 2025$29.04$30.02$30.34
21 Nov 2025$28.61$30.14$30.28
28 Nov 2025$29.58$30.26$30.22
5 Dec 2025$29.52$30.43$30.06
12 Dec 2025$28.50$30.33$29.90
19 Dec 2025$28.45$30.02$29.74
26 Dec 2025$28.49$29.76$29.62
2 Jan 2026$28.26$29.53$29.50
9 Jan 2026$29.66$29.40$29.37
16 Jan 2026$31.63$29.38$29.30
23 Jan 2026$33.61$29.47$29.35
30 Jan 2026$33.89$29.77$29.50
6 Feb 2026$34.91$30.35$29.68
13 Feb 2026$33.16$30.85$29.84
20 Feb 2026$31.91$31.07$29.87
27 Feb 2026$30.10$31.36$29.90
6 Mar 2026$28.63$31.45$29.85
13 Mar 2026$27.76$31.41$29.79
20 Mar 2026$28.15$31.35$29.72
27 Mar 2026$29.39$31.28$29.66
2 Apr 2026$34.84$31.41$29.73
10 Apr 2026$33.36$31.46$29.85
17 Apr 2026$34.53$31.39$29.97
24 Apr 2026$33.31$31.31$30.08
1 May 2026$33.38$31.41$30.18
8 May 2026$34.99$31.75$30.37
15 May 2026$37.48$32.58$30.64
22 May 2026$36.80$33.47$30.90
29 May 2026$42.19$34.41$31.15
5 Jun 2026$42.80$35.82$31.50
12 Jun 2026$44.28$37.02$31.87
18 Jun 2026$44.99$37.84$32.18
26 Jun 2026$55.08$39.51$32.71
2 Jul 2026$54.58$41.01$33.23
10 Jul 2026$51.94$43.04$33.88
17 Jul 2026$52.72$44.82$34.49
24 Jul 2026$52.89$46.49$35.03
31 Jul 2026$48.99$47.73$35.50
7 Aug 2026$49.17$48.93$35.95
14 Aug 2026$49.06$49.71$36.43
21 Aug 2026$48.33$50.29$36.88
28 Aug 2026$47.41$50.72$37.31
4 Sep 2026$46.10$50.57$37.71
11 Sep 2026$45.97$49.99$38.05
18 Sep 2026$43.39$49.09$38.47
25 Sep 2026$40.85$48.13$38.79
2 Oct 2026$41.75$46.95$39.09
9 Oct 2026$40.61$45.99$39.42
16 Oct 2026$41.22$45.08$39.72
23 Oct 2026$43.63$44.49$40.10
30 Oct 2026$45.34$44.06$40.48
4 Nov 2026$45.89$43.86$40.68
Weekly closing price ($) with its 50-day and 200-day averages. The strip under the chart shows the phase: tan sideways, green rising, yellow stalling near a high, orange falling. 3-year window.

5Y

Nov 2026: $45.89, 12.8% above its 200-day average. The price has been rising for 26 weeks.

  • Price $45.89
  • 50-day avg $43.86
  • 200-day avg $40.68
Nov 2026: $45.89, 12.8% above its 200-day average. The price has been rising for 26 weeks.
WeekPrice50-day avg200-day avg
29 Oct 2021$30.29$30.80$24.60
12 Nov 2021$23.98$30.22$24.90
26 Nov 2021$22.47$28.92$24.94
10 Dec 2021$21.83$27.14$25.06
23 Dec 2021$24.09$25.67$25.24
7 Jan 2022$24.01$24.22$25.44
21 Jan 2022$24.00$23.37$25.69
4 Feb 2022$23.71$23.64$25.94
18 Feb 2022$25.08$24.00$26.05
4 Mar 2022$23.18$24.27$26.14
18 Mar 2022$26.12$24.49$26.25
1 Apr 2022$28.06$24.93$26.37
14 Apr 2022$29.36$25.67$26.58
29 Apr 2022$28.85$26.69$26.78
13 May 2022$26.88$27.30$26.94
27 May 2022$30.54$28.28$27.01
10 Jun 2022$27.46$28.69$26.98
24 Jun 2022$29.71$28.58$26.86
8 Jul 2022$31.85$28.97$26.89
22 Jul 2022$28.82$29.23$26.81
5 Aug 2022$25.77$28.87$26.57
19 Aug 2022$25.26$28.15$26.34
2 Sep 2022$24.51$27.49$26.24
16 Sep 2022$23.37$26.29$26.30
30 Sep 2022$22.33$24.77$26.31
14 Oct 2022$22.62$23.90$26.27
28 Oct 2022$23.33$23.27$26.21
11 Nov 2022$23.59$23.07$26.14
25 Nov 2022$24.20$22.96$26.10
9 Dec 2022$24.70$23.44$26.13
23 Dec 2022$25.49$24.02$26.20
6 Jan 2023$27.11$24.54$26.23
20 Jan 2023$27.72$25.27$26.23
3 Feb 2023$27.35$26.27$26.19
17 Feb 2023$28.07$26.80$26.12
3 Mar 2023$27.25$27.16$26.11
17 Mar 2023$26.03$27.37$25.98
31 Mar 2023$28.19$27.33$25.90
14 Apr 2023$29.35$27.48$25.92
28 Apr 2023$28.55$27.85$25.83
12 May 2023$31.16$28.35$25.86
26 May 2023$29.32$29.01$26.09
9 Jun 2023$31.13$29.63$26.29
23 Jun 2023$33.34$30.26$26.64
7 Jul 2023$29.88$30.59$26.98
21 Jul 2023$31.92$30.93$27.40
4 Aug 2023$27.60$30.63$27.73
18 Aug 2023$29.28$30.40$28.02
1 Sep 2023$29.27$29.67$28.26
15 Sep 2023$29.60$29.29$28.53
29 Sep 2023$28.01$29.01$28.73
13 Oct 2023$27.73$28.69$28.86
27 Oct 2023$23.90$28.20$28.85
10 Nov 2023$23.80$27.44$28.68
24 Nov 2023$24.39$26.45$28.51
8 Dec 2023$25.86$25.62$28.38
22 Dec 2023$27.92$25.43$28.39
5 Jan 2024$28.56$25.67$28.46
19 Jan 2024$27.90$26.36$28.50
2 Feb 2024$26.74$27.07$28.43
16 Feb 2024$32.18$27.81$28.39
1 Mar 2024$30.24$28.36$28.36
15 Mar 2024$28.75$28.59$28.32
28 Mar 2024$27.07$28.39$28.18
12 Apr 2024$24.42$28.02$27.86
26 Apr 2024$24.68$27.41$27.54
10 May 2024$24.05$26.22$27.20
24 May 2024$24.02$25.23$26.99
7 Jun 2024$23.91$24.56$26.76
21 Jun 2024$24.95$24.25$26.60
5 Jul 2024$24.29$24.28$26.36
19 Jul 2024$24.83$24.21$26.12
2 Aug 2024$27.72$24.75$26.06
16 Aug 2024$27.25$25.34$26.13
30 Aug 2024$28.45$26.07$26.31
13 Sep 2024$27.66$26.57$26.45
27 Sep 2024$27.53$27.32$26.57
11 Oct 2024$28.91$27.60$26.60
25 Oct 2024$26.09$27.81$26.57
8 Nov 2024$28.86$27.66$26.54
22 Nov 2024$28.78$27.88$26.60
6 Dec 2024$31.46$28.29$26.63
20 Dec 2024$29.71$28.80$26.67
3 Jan 2025$29.04$28.94$26.70
17 Jan 2025$29.47$29.34$26.77
31 Jan 2025$31.53$29.75$27.02
14 Feb 2025$35.89$30.54$27.44
28 Feb 2025$34.33$31.32$27.93
14 Mar 2025$34.03$32.24$28.44
28 Mar 2025$33.21$33.33$28.95
11 Apr 2025$27.00$33.16$29.22
25 Apr 2025$27.84$32.39$29.35
9 May 2025$30.13$31.33$29.65
23 May 2025$29.35$30.60$29.81
6 Jun 2025$31.71$29.99$30.00
20 Jun 2025$29.09$29.74$30.09
3 Jul 2025$28.85$30.02$30.17
18 Jul 2025$29.22$30.09$30.26
1 Aug 2025$26.55$29.26$30.20
15 Aug 2025$29.05$28.62$30.17
29 Aug 2025$28.97$28.32$30.25
12 Sep 2025$26.97$28.22$30.25
26 Sep 2025$27.89$27.85$30.14
10 Oct 2025$31.21$28.60$30.16
24 Oct 2025$29.80$29.40$30.26
7 Nov 2025$32.89$29.80$30.34
21 Nov 2025$28.61$30.14$30.28
5 Dec 2025$29.52$30.43$30.06
19 Dec 2025$28.45$30.02$29.74
2 Jan 2026$28.26$29.53$29.50
16 Jan 2026$31.63$29.38$29.30
30 Jan 2026$33.89$29.77$29.50
13 Feb 2026$33.16$30.85$29.84
27 Feb 2026$30.10$31.36$29.90
13 Mar 2026$27.76$31.41$29.79
27 Mar 2026$29.39$31.28$29.66
10 Apr 2026$33.36$31.46$29.85
24 Apr 2026$33.31$31.31$30.08
8 May 2026$34.99$31.75$30.37
22 May 2026$36.80$33.47$30.90
5 Jun 2026$42.80$35.82$31.50
18 Jun 2026$44.99$37.84$32.18
2 Jul 2026$54.58$41.01$33.23
17 Jul 2026$52.72$44.82$34.49
31 Jul 2026$48.99$47.73$35.50
14 Aug 2026$49.06$49.71$36.43
28 Aug 2026$47.41$50.72$37.31
11 Sep 2026$45.97$49.99$38.05
25 Sep 2026$40.85$48.13$38.79
9 Oct 2026$40.61$45.99$39.42
23 Oct 2026$43.63$44.49$40.10
4 Nov 2026$45.89$43.86$40.68
Weekly closing price ($) with its 50-day and 200-day averages. The strip under the chart shows the phase: tan sideways, green rising, yellow stalling near a high, orange falling. 5-year window.

10Y

Nov 2026: $45.89, 12.8% above its 200-day average. The price has been rising for 26 weeks.

  • Price $45.89
  • 50-day avg $43.86
  • 200-day avg $40.68
Nov 2026: $45.89, 12.8% above its 200-day average. The price has been rising for 26 weeks.
WeekPrice50-day avg200-day avg
28 Oct 2016$51.01$47.14–
18 Nov 2016$58.44$50.28–
9 Dec 2016$55.47$52.60–
30 Dec 2016$55.58$55.76–
20 Jan 2017$55.98$57.01–
10 Feb 2017$55.11$55.94–
3 Mar 2017$60.97$55.97–
24 Mar 2017$58.88$56.24–
13 Apr 2017$57.16$57.15–
5 May 2017$59.69$57.97$53.46
26 May 2017$57.70$58.08$54.14
16 Jun 2017$57.15$58.14$55.09
7 Jul 2017$59.53$58.50$55.87
28 Jul 2017$55.22$58.30$56.63
18 Aug 2017$50.90$56.56$56.95
8 Sep 2017$50.56$54.23$56.49
29 Sep 2017$50.84$52.15$56.10
20 Oct 2017$50.58$51.03$55.69
10 Nov 2017$47.85$50.64$55.18
1 Dec 2017$53.70$50.29$54.83
22 Dec 2017$53.04$50.67$54.51
12 Jan 2018$58.71$52.04$54.34
2 Feb 2018$63.42$54.81$54.39
23 Feb 2018$58.60$56.60$54.43
16 Mar 2018$61.25$58.44$54.54
6 Apr 2018$42.18$57.56$54.18
27 Apr 2018$44.74$53.76$53.14
18 May 2018$46.27$49.28$52.25
8 Jun 2018$48.61$45.53$51.88
29 Jun 2018$41.16$45.98$51.57
20 Jul 2018$45.04$45.69$51.02
10 Aug 2018$44.03$45.12$50.53
31 Aug 2018$44.84$44.02$50.21
21 Sep 2018$41.56$43.64$49.52
12 Oct 2018$41.64$43.16$48.79
2 Nov 2018$37.74$42.02$47.70
23 Nov 2018$34.34$39.78$46.12
14 Dec 2018$32.82$38.04$44.46
4 Jan 2019$30.00$34.71$42.48
25 Jan 2019$34.07$32.82$41.10
15 Feb 2019$32.54$32.10$40.18
8 Mar 2019$31.93$32.34$39.35
29 Mar 2019$36.49$33.38$38.40
18 Apr 2019$33.58$33.98$37.64
10 May 2019$26.30$33.06$36.60
31 May 2019$21.54$30.42$35.19
21 Jun 2019$22.59$26.56$33.51
12 Jul 2019$22.53$23.72$32.23
2 Aug 2019$22.30$22.64$30.71
23 Aug 2019$20.07$22.28$29.31
13 Sep 2019$22.30$21.89$28.29
4 Oct 2019$18.49$21.09$27.20
25 Oct 2019$19.48$20.00$26.34
15 Nov 2019$21.00$19.75$25.36
6 Dec 2019$20.95$19.53$24.52
27 Dec 2019$20.43$20.25$23.66
17 Jan 2020$19.24$20.34$22.59
7 Feb 2020$18.96$19.75$21.40
28 Feb 2020$20.84$19.27$20.78
20 Mar 2020$13.38$18.22$20.26
9 Apr 2020$15.43$17.03$19.70
1 May 2020$13.31$16.15$19.16
22 May 2020$16.86$15.03$18.64
12 Jun 2020$16.36$15.77$18.32
2 Jul 2020$19.59$16.63$18.13
24 Jul 2020$19.79$18.03$18.12
14 Aug 2020$18.56$18.76$18.15
4 Sep 2020$16.34$18.57$17.92
25 Sep 2020$16.74$17.94$17.67
16 Oct 2020$17.13$17.22$17.38
6 Nov 2020$17.00$16.75$17.18
27 Nov 2020$18.50$17.10$17.17
18 Dec 2020$22.00$18.07$17.19
8 Jan 2021$20.38$19.07$17.55
29 Jan 2021$20.99$20.44$18.05
19 Feb 2021$19.58$21.23$18.47
12 Mar 2021$19.42$20.69$18.74
1 Apr 2021$19.15$20.26$18.94
23 Apr 2021$21.28$19.54$19.00
14 May 2021$22.26$20.33$19.18
4 Jun 2021$23.08$21.11$19.45
25 Jun 2021$24.13$22.73$20.02
16 Jul 2021$23.71$23.66$20.54
6 Aug 2021$28.56$24.75$21.21
27 Aug 2021$31.11$26.41$22.18
17 Sep 2021$30.11$28.01$23.05
8 Oct 2021$31.70$30.05$23.85
29 Oct 2021$30.29$30.80$24.60
19 Nov 2021$23.24$29.55$24.93
10 Dec 2021$21.83$27.14$25.06
31 Dec 2021$23.26$24.91$25.34
21 Jan 2022$24.00$23.37$25.69
11 Feb 2022$23.20$23.76$25.98
4 Mar 2022$23.18$24.27$26.14
25 Mar 2022$27.43$24.70$26.31
14 Apr 2022$29.36$25.67$26.58
6 May 2022$27.63$27.05$26.89
27 May 2022$30.54$28.28$27.01
17 Jun 2022$28.03$28.61$26.89
8 Jul 2022$31.85$28.97$26.89
29 Jul 2022$25.60$29.23$26.71
19 Aug 2022$25.26$28.15$26.34
9 Sep 2022$24.01$27.01$26.26
30 Sep 2022$22.33$24.77$26.31
21 Oct 2022$22.26$23.59$26.25
11 Nov 2022$23.59$23.07$26.14
2 Dec 2022$26.09$23.15$26.13
23 Dec 2022$25.49$24.02$26.20
13 Jan 2023$27.31$24.94$26.22
3 Feb 2023$27.35$26.27$26.19
24 Feb 2023$27.18$26.98$26.11
17 Mar 2023$26.03$27.37$25.98
6 Apr 2023$29.22$27.43$25.93
28 Apr 2023$28.55$27.85$25.83
19 May 2023$30.48$28.71$25.99
9 Jun 2023$31.13$29.63$26.29
30 Jun 2023$31.30$30.54$26.85
21 Jul 2023$31.92$30.93$27.40
11 Aug 2023$28.03$30.51$27.87
1 Sep 2023$29.27$29.67$28.26
22 Sep 2023$29.02$29.27$28.64
13 Oct 2023$27.73$28.69$28.86
3 Nov 2023$24.79$27.77$28.76
24 Nov 2023$24.39$26.45$28.51
15 Dec 2023$27.42$25.50$28.38
5 Jan 2024$28.56$25.67$28.46
26 Jan 2024$27.74$26.73$28.48
16 Feb 2024$32.18$27.81$28.39
8 Mar 2024$29.25$28.54$28.33
28 Mar 2024$27.07$28.39$28.18
19 Apr 2024$23.85$27.73$27.68
10 May 2024$24.05$26.22$27.20
31 May 2024$23.40$24.87$26.89
21 Jun 2024$24.95$24.25$26.60
12 Jul 2024$23.57$24.19$26.22
2 Aug 2024$27.72$24.75$26.06
23 Aug 2024$27.95$25.72$26.21
13 Sep 2024$27.66$26.57$26.45
4 Oct 2024$28.97$27.60$26.61
25 Oct 2024$26.09$27.81$26.57
15 Nov 2024$28.19$27.79$26.57
6 Dec 2024$31.46$28.29$26.63
27 Dec 2024$29.55$28.89$26.69
17 Jan 2025$29.47$29.34$26.77
7 Feb 2025$31.57$30.09$27.21
28 Feb 2025$34.33$31.32$27.93
21 Mar 2025$34.60$32.80$28.71
11 Apr 2025$27.00$33.16$29.22
2 May 2025$31.78$31.76$29.50
23 May 2025$29.35$30.60$29.81
13 Jun 2025$29.83$29.77$30.07
3 Jul 2025$28.85$30.02$30.17
25 Jul 2025$26.13$29.70$30.21
15 Aug 2025$29.05$28.62$30.17
5 Sep 2025$29.94$28.35$30.26
26 Sep 2025$27.89$27.85$30.14
17 Oct 2025$30.26$29.09$30.21
7 Nov 2025$32.89$29.80$30.34
28 Nov 2025$29.58$30.26$30.22
19 Dec 2025$28.45$30.02$29.74
9 Jan 2026$29.66$29.40$29.37
30 Jan 2026$33.89$29.77$29.50
20 Feb 2026$31.91$31.07$29.87
13 Mar 2026$27.76$31.41$29.79
2 Apr 2026$34.84$31.41$29.73
24 Apr 2026$33.31$31.31$30.08
15 May 2026$37.48$32.58$30.64
5 Jun 2026$42.80$35.82$31.50
26 Jun 2026$55.08$39.51$32.71
17 Jul 2026$52.72$44.82$34.49
7 Aug 2026$49.17$48.93$35.95
28 Aug 2026$47.41$50.72$37.31
18 Sep 2026$43.39$49.09$38.47
9 Oct 2026$40.61$45.99$39.42
30 Oct 2026$45.34$44.06$40.48
4 Nov 2026$45.89$43.86$40.68
Weekly closing price ($) with its 50-day and 200-day averages. The strip under the chart shows the phase: tan sideways, green rising, yellow stalling near a high, orange falling. 10-year window.

Price stage: Sideways from Oct 2025 to Jan 2026; Sideways from Jan 2026 to Feb 2026; Falling in Mar 2026; Sideways from Apr 2026 to May 2026; Rising from May 2026 to Nov 2026.

Price stage: Sideways from Nov 2023 to Feb 2024; Rising from Feb 2024 to Mar 2024; Falling from Apr 2024 to Jul 2024; Sideways from Jul 2024 to Jan 2025; Rising from Jan 2025 to Apr 2025; Sideways in Apr 2025; Rising from May 2025 to Jun 2025; Sideways from Jun 2025 to Sep 2025; Rising from Oct 2025 to Nov 2025; Sideways from Nov 2025 to Jan 2026; Sideways from Jan 2026 to Feb 2026; Falling in Mar 2026; Sideways from Apr 2026 to May 2026; Rising from May 2026 to Nov 2026.

Price stage: Sideways from Oct 2021 to Mar 2022; Rising from Apr 2022 to Jul 2022; Sideways from Aug 2022 to Oct 2022; Falling from Nov 2022 to Dec 2022; Sideways from Jan 2023 to Jun 2023; Rising from Jun 2023 to Sep 2023; Sideways from Sep 2023 to Feb 2024; Rising from Feb 2024 to Mar 2024; Falling from Apr 2024 to Jul 2024; Sideways from Aug 2024 to Jan 2025; Rising from Jan 2025 to Jun 2025; Sideways from Jun 2025 to Jan 2026; Sideways from Jan 2026 to May 2026; Rising from May 2026 to Nov 2026.

Price stage: Sideways from Dec 2017 to Mar 2018; Falling from Apr 2018 to Jun 2020; Sideways from Jul 2020 to Aug 2020; Falling from Sep 2020 to Nov 2020; Sideways from Nov 2020 to Jan 2021; Rising from Feb 2021 to Oct 2021; Sideways from Nov 2021 to Mar 2022; Rising from Mar 2022 to Jul 2022; Sideways from Jul 2022 to Oct 2022; Falling from Nov 2022 to Dec 2022; Sideways from Jan 2023 to Jun 2023; Rising from Jun 2023 to Sep 2023; Sideways from Oct 2023 to Mar 2024; Falling from Apr 2024 to Jul 2024; Sideways from Aug 2024 to Jan 2025; Rising from Feb 2025 to May 2025; Sideways from May 2025 to Dec 2025; Sideways from Jan 2026 to Apr 2026; Rising from May 2026 to Nov 2026.

Week by week since 2016: did it beat the S&P 500 over the past 13 weeks?

Ahead in 217 of 527 weeks

Week by week since 2016: did it beat the S&P 500 over the past 13 weeks?
Week13-week return vs S&P 500
8 Jul 2016no S&P 500 reading
15 Jul 2016no S&P 500 reading
22 Jul 2016no S&P 500 reading
29 Jul 2016no S&P 500 reading
5 Aug 2016no S&P 500 reading
12 Aug 2016no S&P 500 reading
19 Aug 2016no S&P 500 reading
26 Aug 2016no S&P 500 reading
2 Sep 2016no S&P 500 reading
9 Sep 2016no S&P 500 reading
16 Sep 2016no S&P 500 reading
23 Sep 2016no S&P 500 reading
30 Sep 2016no S&P 500 reading
7 Oct 2016−7.7%
14 Oct 2016−9.8%
21 Oct 2016+13.2%
28 Oct 2016+4.3%
4 Nov 2016+11.3%
11 Nov 2016+26.3%
18 Nov 2016+31.7%
25 Nov 2016+30.4%
2 Dec 2016+24.1%
9 Dec 2016+16.0%
16 Dec 2016+8.6%
23 Dec 2016+12.5%
30 Dec 2016+14.8%
6 Jan 2017+24.8%
13 Jan 2017+24.6%
20 Jan 2017−5.3%
27 Jan 2017−1.2%
3 Feb 2017−4.2%
10 Feb 2017−12.8%
17 Feb 2017−14.2%
24 Feb 2017−16.9%
3 Mar 2017−0.1%
10 Mar 2017−1.8%
17 Mar 2017−0.4%
24 Mar 2017−2.1%
31 Mar 2017−0.2%
7 Apr 2017−5.1%
13 Apr 2017+0.7%
21 Apr 2017−2.4%
28 Apr 2017+3.2%
5 May 2017+4.1%
12 May 2017+2.8%
19 May 2017+4.8%
26 May 2017+6.8%
2 Jun 2017−5.0%
9 Jun 2017+5.4%
16 Jun 2017−6.0%
23 Jun 2017−4.7%
30 Jun 2017−3.5%
7 Jul 2017−1.5%
14 Jul 2017−2.6%
21 Jul 2017−3.2%
28 Jul 2017−8.9%
4 Aug 2017−13.1%
11 Aug 2017−13.3%
18 Aug 2017−14.0%
25 Aug 2017−13.8%
1 Sep 2017−17.8%
8 Sep 2017−19.3%
15 Sep 2017−11.7%
22 Sep 2017−16.4%
29 Sep 2017−16.2%
6 Oct 2017−18.6%
13 Oct 2017−18.4%
20 Oct 2017−16.5%
27 Oct 2017−14.1%
3 Nov 2017−9.6%
10 Nov 2017−13.5%
17 Nov 2017−11.2%
24 Nov 2017−5.2%
1 Dec 2017+1.3%
8 Dec 2017−3.1%
15 Dec 2017−5.8%
22 Dec 2017−1.9%
29 Dec 2017+1.4%
5 Jan 2018−2.4%
12 Jan 2018+7.7%
19 Jan 2018+3.7%
26 Jan 2018+7.6%
2 Feb 2018+17.8%
9 Feb 2018+11.3%
16 Feb 2018+33.1%
23 Feb 2018+9.3%
2 Mar 2018+10.1%
9 Mar 2018+5.6%
16 Mar 2018+13.5%
23 Mar 2018+13.4%
29 Mar 2018+7.3%
6 Apr 2018−17.1%
13 Apr 2018−23.0%
20 Apr 2018−14.4%
27 Apr 2018−17.5%
4 May 2018−28.1%
11 May 2018−17.7%
18 May 2018−30.6%
25 May 2018−21.0%
1 Jun 2018−22.4%
8 Jun 2018−16.6%
15 Jun 2018−18.9%
22 Jun 2018−30.7%
29 Jun 2018−32.1%
6 Jul 2018−5.2%
13 Jul 2018−1.4%
20 Jul 2018−7.0%
27 Jul 2018−7.4%
3 Aug 2018−5.9%
10 Aug 2018−9.5%
17 Aug 2018−8.8%
24 Aug 2018−7.7%
31 Aug 2018−11.9%
7 Sep 2018−19.7%
14 Sep 2018−26.1%
21 Sep 2018−12.1%
28 Sep 2018−4.1%
5 Oct 2018+0.4%
12 Oct 2018−4.6%
19 Oct 2018−9.6%
26 Oct 2018+0.0%
2 Nov 2018−9.6%
9 Nov 2018−12.5%
16 Nov 2018−18.6%
23 Nov 2018−15.0%
30 Nov 2018−13.7%
7 Dec 2018−8.1%
14 Dec 2018−6.8%
21 Dec 2018−14.0%
28 Dec 2018−18.1%
4 Jan 2019−20.4%
11 Jan 2019−15.8%
18 Jan 2019−11.4%
25 Jan 2019−17.8%
1 Feb 2019−11.7%
8 Feb 2019−15.5%
15 Feb 2019−7.0%
22 Feb 2019−8.7%
1 Mar 2019−7.2%
8 Mar 2019−10.2%
15 Mar 2019−4.3%
22 Mar 2019+3.4%
29 Mar 2019+14.1%
5 Apr 2019+9.5%
12 Apr 2019−6.8%
18 Apr 2019−10.5%
26 Apr 2019−20.8%
3 May 2019−22.6%
10 May 2019−21.3%
17 May 2019−26.7%
24 May 2019−29.7%
31 May 2019−35.6%
7 Jun 2019−33.3%
14 Jun 2019−38.5%
21 Jun 2019−38.8%
28 Jun 2019−42.0%
5 Jul 2019−42.3%
12 Jul 2019−37.8%
19 Jul 2019−33.2%
26 Jul 2019−35.6%
2 Aug 2019−21.4%
9 Aug 2019−16.8%
16 Aug 2019−13.9%
23 Aug 2019−16.9%
30 Aug 2019−8.8%
6 Sep 2019−14.9%
13 Sep 2019−2.2%
20 Sep 2019−7.6%
27 Sep 2019−13.7%
4 Oct 2019−17.2%
11 Oct 2019−18.6%
18 Oct 2019−22.3%
25 Oct 2019−5.1%
1 Nov 2019−16.3%
8 Nov 2019−15.3%
15 Nov 2019−10.9%
22 Nov 2019−4.5%
29 Nov 2019−7.3%
6 Dec 2019−2.2%
13 Dec 2019−11.8%
20 Dec 2019−8.8%
27 Dec 2019−5.2%
3 Jan 2020−5.4%
10 Jan 2020−1.6%
17 Jan 2020−5.4%
24 Jan 2020−18.6%
31 Jan 2020−16.7%
7 Feb 2020−13.2%
14 Feb 2020−23.7%
21 Feb 2020−10.9%
28 Feb 2020+4.9%
6 Mar 2020−3.8%
13 Mar 2020−7.5%
20 Mar 2020−7.4%
27 Mar 2020−8.0%
3 Apr 2020−3.7%
9 Apr 2020−6.4%
17 Apr 2020−1.3%
24 Apr 2020+5.1%
1 May 2020−11.4%
8 May 2020−9.0%
15 May 2020+1.1%
22 May 2020−5.3%
29 May 2020−24.2%
5 Jun 2020−16.8%
12 Jun 2020−11.6%
19 Jun 2020+2.2%
26 Jun 2020+12.2%
2 Jul 2020+12.9%
10 Jul 2020+13.4%
17 Jul 2020+6.7%
24 Jul 2020+9.8%
31 Jul 2020+19.8%
7 Aug 2020+10.3%
14 Aug 2020+3.9%
21 Aug 2020−13.7%
28 Aug 2020−15.3%
4 Sep 2020−12.2%
11 Sep 2020−3.5%
18 Sep 2020−8.9%
25 Sep 2020−20.5%
2 Oct 2020−26.3%
8 Oct 2020−23.6%
16 Oct 2020−19.9%
23 Oct 2020−24.9%
30 Oct 2020−9.8%
6 Nov 2020−13.8%
13 Nov 2020−10.4%
20 Nov 2020+2.2%
27 Nov 2020+9.4%
4 Dec 2020+8.8%
11 Dec 2020+12.8%
18 Dec 2020+10.4%
24 Dec 2020+15.9%
31 Dec 2020+14.4%
8 Jan 2021+11.0%
15 Jan 2021+22.4%
22 Jan 2021+24.7%
29 Jan 2021+15.8%
5 Feb 2021+20.6%
12 Feb 2021+4.0%
19 Feb 2021−2.4%
26 Feb 2021−1.7%
5 Mar 2021−2.7%
12 Mar 2021−16.4%
19 Mar 2021−14.4%
26 Mar 2021−16.4%
1 Apr 2021−11.2%
9 Apr 2021−14.6%
16 Apr 2021−22.2%
23 Apr 2021−12.9%
30 Apr 2021−8.0%
7 May 2021−10.4%
14 May 2021+4.0%
21 May 2021+6.9%
28 May 2021+8.6%
4 Jun 2021+9.6%
11 Jun 2021+21.2%
18 Jun 2021+15.3%
25 Jun 2021+15.9%
2 Jul 2021+23.8%
9 Jul 2021+27.5%
16 Jul 2021+16.0%
23 Jul 2021+9.5%
30 Jul 2021+12.5%
6 Aug 2021+25.0%
13 Aug 2021+22.1%
20 Aug 2021+29.5%
27 Aug 2021+30.0%
3 Sep 2021+22.2%
10 Sep 2021+17.0%
17 Sep 2021+16.9%
24 Sep 2021+28.9%
1 Oct 2021+21.9%
8 Oct 2021+24.5%
15 Oct 2021+30.2%
22 Oct 2021+23.0%
29 Oct 2021+12.4%
5 Nov 2021+0.3%
12 Nov 2021−21.4%
19 Nov 2021−28.9%
26 Nov 2021−29.7%
3 Dec 2021−26.3%
10 Dec 2021−34.2%
17 Dec 2021−26.6%
23 Dec 2021−30.9%
31 Dec 2021−34.1%
7 Jan 2022−30.7%
14 Jan 2022−24.5%
21 Jan 2022−18.9%
28 Jan 2022−13.4%
4 Feb 2022−17.6%
11 Feb 2022+2.5%
18 Feb 2022+15.3%
25 Feb 2022+15.0%
4 Mar 2022+9.9%
11 Mar 2022+22.4%
18 Mar 2022+15.2%
25 Mar 2022+17.7%
1 Apr 2022+25.3%
8 Apr 2022+27.4%
14 Apr 2022+22.1%
22 Apr 2022+20.2%
29 Apr 2022+21.8%
6 May 2022+24.9%
13 May 2022+24.7%
20 May 2022+29.9%
27 May 2022+28.2%
3 Jun 2022+31.5%
10 Jun 2022+19.8%
17 Jun 2022+25.0%
24 Jun 2022+22.1%
1 Jul 2022+24.6%
8 Jul 2022+20.7%
15 Jul 2022+14.0%
22 Jul 2022+9.5%
29 Jul 2022−11.3%
5 Aug 2022−7.2%
12 Aug 2022−9.0%
19 Aug 2022−24.1%
26 Aug 2022−17.3%
2 Sep 2022−11.9%
9 Sep 2022−16.9%
16 Sep 2022−22.0%
23 Sep 2022−19.2%
30 Sep 2022−20.5%
7 Oct 2022−23.9%
14 Oct 2022−17.3%
21 Oct 2022−17.5%
28 Oct 2022−3.3%
4 Nov 2022+2.0%
11 Nov 2022−3.1%
18 Nov 2022−1.0%
25 Nov 2022−0.7%
2 Dec 2022+2.7%
9 Dec 2022+6.1%
16 Dec 2022+9.8%
23 Dec 2022+10.1%
30 Dec 2022+9.9%
6 Jan 2023+15.5%
13 Jan 2023+9.3%
20 Jan 2023+18.8%
27 Jan 2023+20.1%
3 Feb 2023+4.5%
10 Feb 2023+12.4%
17 Feb 2023+16.9%
24 Feb 2023+13.8%
3 Mar 2023+5.1%
10 Mar 2023+9.6%
17 Mar 2023+0.2%
24 Mar 2023+0.6%
31 Mar 2023+0.8%
6 Apr 2023+2.3%
14 Apr 2023+4.0%
21 Apr 2023+1.9%
28 Apr 2023−4.1%
5 May 2023+7.6%
12 May 2023+14.2%
19 May 2023+5.8%
26 May 2023+1.9%
2 Jun 2023+2.4%
9 Jun 2023+5.6%
16 Jun 2023+11.0%
23 Jun 2023+16.4%
30 Jun 2023+2.8%
7 Jul 2023−4.9%
14 Jul 2023−5.2%
21 Jul 2023−1.1%
28 Jul 2023−9.1%
4 Aug 2023−14.6%
11 Aug 2023−18.3%
18 Aug 2023−8.2%
25 Aug 2023−12.1%
1 Sep 2023−6.3%
8 Sep 2023−11.0%
15 Sep 2023−8.9%
22 Sep 2023−12.3%
29 Sep 2023−6.9%
6 Oct 2023−2.0%
13 Oct 2023−4.9%
20 Oct 2023−8.5%
27 Oct 2023−6.8%
3 Nov 2023−7.5%
10 Nov 2023−14.0%
17 Nov 2023−20.5%
24 Nov 2023−13.7%
1 Dec 2023−18.8%
8 Dec 2023−13.7%
15 Dec 2023−13.2%
22 Dec 2023−13.8%
29 Dec 2023−12.2%
5 Jan 2024−9.4%
12 Jan 2024−8.8%
19 Jan 2024−11.3%
26 Jan 2024−2.6%
2 Feb 2024−5.9%
9 Feb 2024+1.0%
16 Feb 2024+21.9%
23 Feb 2024+9.7%
1 Mar 2024+12.8%
8 Mar 2024+1.9%
15 Mar 2024−3.8%
22 Mar 2024−12.3%
28 Mar 2024−12.5%
5 Apr 2024−19.3%
12 Apr 2024−20.6%
19 Apr 2024−17.2%
26 Apr 2024−15.3%
3 May 2024−13.5%
10 May 2024−15.9%
17 May 2024−30.9%
24 May 2024−23.0%
31 May 2024−25.5%
7 Jun 2024−22.6%
14 Jun 2024−21.2%
21 Jun 2024−13.0%
28 Jun 2024−15.0%
5 Jul 2024−14.0%
12 Jul 2024−13.1%
19 Jul 2024−6.8%
26 Jul 2024+5.8%
2 Aug 2024+11.0%
9 Aug 2024+6.1%
16 Aug 2024+8.1%
23 Aug 2024+10.2%
30 Aug 2024+14.7%
6 Sep 2024+11.1%
13 Sep 2024+9.4%
20 Sep 2024+10.1%
27 Sep 2024+9.2%
4 Oct 2024+16.0%
11 Oct 2024+19.2%
18 Oct 2024+7.4%
25 Oct 2024−12.8%
1 Nov 2024−11.7%
8 Nov 2024−1.5%
15 Nov 2024−2.2%
22 Nov 2024−3.0%
29 Nov 2024−4.9%
6 Dec 2024+4.6%
13 Dec 2024+2.8%
20 Dec 2024+0.0%
27 Dec 2024+3.2%
3 Jan 2025−3.1%
10 Jan 2025−3.0%
17 Jan 2025+2.0%
24 Jan 2025+14.6%
31 Jan 2025+13.7%
7 Feb 2025+9.0%
14 Feb 2025+23.2%
21 Feb 2025+22.0%
28 Feb 2025+19.7%
7 Mar 2025+14.4%
14 Mar 2025+18.4%
21 Mar 2025+21.1%
28 Mar 2025+19.0%
4 Apr 2025+18.2%
11 Apr 2025+4.2%
17 Apr 2025+3.5%
25 Apr 2025−1.3%
2 May 2025+6.6%
9 May 2025+1.5%
16 May 2025−9.9%
23 May 2025−13.4%
30 May 2025−10.0%
6 Jun 2025−11.7%
13 Jun 2025−18.4%
20 Jun 2025−21.3%
27 Jun 2025−23.9%
3 Jul 2025−27.8%
11 Jul 2025−4.6%
18 Jul 2025−11.0%
25 Jul 2025−21.8%
1 Aug 2025−26.2%
8 Aug 2025−24.3%
15 Aug 2025−15.8%
22 Aug 2025−10.1%
29 Aug 2025−14.8%
5 Sep 2025−13.6%
12 Sep 2025−19.7%
19 Sep 2025−16.2%
26 Sep 2025−10.8%
3 Oct 2025+0.6%
10 Oct 2025−1.6%
17 Oct 2025−2.3%
24 Oct 2025+7.7%
31 Oct 2025+5.9%
7 Nov 2025+17.8%
14 Nov 2025−4.5%
21 Nov 2025−6.0%
28 Nov 2025−3.8%
5 Dec 2025−7.3%
12 Dec 2025+2.0%
19 Dec 2025−0.2%
26 Dec 2025−2.2%
2 Jan 2026−11.1%
9 Jan 2026−11.3%
16 Jan 2026+0.4%
23 Jan 2026+11.0%
30 Jan 2026+8.9%
6 Feb 2026+3.2%
13 Feb 2026+12.7%
20 Feb 2026+6.9%
27 Feb 2026+1.4%
6 Mar 2026−1.1%
13 Mar 2026+0.3%
20 Mar 2026+3.7%
27 Mar 2026+11.3%
2 Apr 2026+27.3%
10 Apr 2026+14.6%
17 Apr 2026+6.5%
24 Apr 2026−4.5%
1 May 2026−5.6%
8 May 2026−6.6%
15 May 2026+4.6%
22 May 2026+7.2%
29 May 2026+29.9%
5 Jun 2026+39.8%
12 Jun 2026+47.5%
18 Jun 2026+44.7%
26 Jun 2026+72.4%
2 Jul 2026+43.1%
10 Jul 2026+44.6%
17 Jul 2026+48.0%
24 Jul 2026+55.3%
31 Jul 2026+43.1%
7 Aug 2026+35.7%
14 Aug 2026+25.9%
21 Aug 2026+28.6%
28 Aug 2026+10.7%
4 Sep 2026+3.3%
11 Sep 2026+0.8%
18 Sep 2026−5.6%
25 Sep 2026−31.6%
2 Oct 2026−26.8%
9 Oct 2026−24.9%
16 Oct 2026−24.5%
23 Oct 2026−20.4%
30 Oct 2026−8.6%
4 Nov 2026−5.8%
Each bar is one week, from 2016 to now (527 weeks with a reading). Green means the stock's return over the previous 13 weeks beat the S&P 500; red means it trailed. The colour is strongest at a gap of 25 percentage points or more. A gap means there is no reading for that week.

Over the last 10 years the share price moved −6% while the S&P 500 moved +261%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 11 September 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

What dividend does Alkermes pay?

Alkermes plc pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Which stock lists is Alkermes on?

Alkermes is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Is Alkermes profitable?

Alkermes plc earned $501 K of net profit in the Jun 2026 quarter, −99.4% on the same quarter a year earlier. Full-year FY25 profit was $242 M. That is 0.1% of the quarter's revenue. The same quarter a year earlier earned $87.1 M. 1 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY25 profit was $242 M (−34.2% on the year before).

FY25 profit $242 M (−34.2% on the year before)

  • Net profit $242 M
FY25 profit $242 M (−34.2% on the year before)
QuarterNet profit
FY21−$48.2 M
FY22−$158 M
FY23$356 M
FY24$367 M
FY25$242 M

Growth on a year earlier

  • Growth on a year earlier −34.2%
Growth on a year earlier
QuarterGrowth on a year earlier
FY21–
FY22–
FY23–
FY243.2%
FY25−34.2%
Top: net profit each year, $ M. Below: growth on the year before, %. 5-year window. A grey bar is lower than the year before.

Jun 2026: $0.5 M (−99.4% on a year earlier)

  • Net profit (quarterly) $0.5 M
Jun 2026: $0.5 M (−99.4% on a year earlier)
QuarterNet profit (quarterly)
Sep 2023$47.8 M
Dec 2023$113 M
Mar 2024$36.8 M
Jun 2024$91.4 M
Sep 2024$92.4 M
Dec 2024$147 M
Mar 2025$22.5 M
Jun 2025$87.1 M
Sep 2025$82.8 M
Dec 2025$49.3 M
Mar 2026−$66.5 M
Jun 2026$0.5 M

Growth on a year earlier

  • Growth on a year earlier −99.4%
Growth on a year earlier
QuarterGrowth on a year earlier
Sep 2023–
Dec 2023–
Mar 2024–
Jun 2024−61.5%
Sep 202493.4%
Dec 202429.9%
Mar 2025−39%
Jun 2025−4.7%
Sep 2025−10.4%
Dec 2025−66.3%
Mar 2026−395.9%
Jun 2026−99.4%
Top: net profit each quarter, $ M. Below: growth on the same quarter a year earlier, %. Last 12 quarters. A grey bar is lower than the quarter before.

Why profit moved: revenue changed +27.0% on a year earlier and the margin moved −8.3 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed −143.0% and revenue +12.2%. Profit is growing slower than sales: rising costs are taking part of the growth.

How much revenue does Alkermes make, and is it growing?

Alkermes plc reported $496 M of revenue in the Jun 2026 quarter, +27.0% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 4 years it has grown 5.9% a year on average. The last full year, FY25, came in at $1.5 B.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to $1.7 B.

FY25 revenue was $1.5 B, −5.2% on the year before.

FY25 revenue $1.5 B (−5.2% on the year before), 5.9% a year over 4 years

  • Revenue $1.5 B
FY25 revenue $1.5 B (−5.2% on the year before), 5.9% a year over 4 years
QuarterRevenue
FY21$1.2 B
FY22$1.1 B
FY23$1.7 B
FY24$1.6 B
FY25$1.5 B

Growth on a year earlier

  • Growth on a year earlier −5.2%
Growth on a year earlier
QuarterGrowth on a year earlier
FY21–
FY22−5.3%
FY2349.6%
FY24−6.4%
FY25−5.2%
Top: revenue each year, $ B. Below: growth on the year before, %. 5-year window. A grey bar is lower than the year before.

Jun 2026: $496 M (+27.0% on a year earlier), the 2nd quarter in a row of growth

  • Revenue (quarterly) $496 M
Jun 2026: $496 M (+27.0% on a year earlier), the 2nd quarter in a row of growth
QuarterRevenue (quarterly)
Sep 2023$381 M
Dec 2023$377 M
Mar 2024$350 M
Jun 2024$399 M
Sep 2024$378 M
Dec 2024$430 M
Mar 2025$307 M
Jun 2025$391 M
Sep 2025$394 M
Dec 2025$385 M
Mar 2026$393 M
Jun 2026$496 M

Growth on a year earlier

  • Growth on a year earlier 27%
Growth on a year earlier
QuarterGrowth on a year earlier
Sep 202351%
Dec 2023–
Mar 202421.8%
Jun 2024−35.4%
Sep 2024−0.7%
Dec 202413.9%
Mar 2025−12.5%
Jun 2025−2.1%
Sep 20254.2%
Dec 2025−10.6%
Mar 202628.2%
Jun 202627%
Top: revenue each quarter, $ M. Below: growth on the same quarter a year earlier, %. Last 12 quarters. A grey bar is lower than the quarter before.

Recent pace: the last four quarters grew +12.2% on average, against 5.9% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +10.8%, against +5.2% a year over the last 8 quarters (accelerating); profit over the last 12 months grew −81.0%, against −52.1% a year (rolling over).

How much of every $100 of sales does Alkermes keep?

Alkermes plc's operating margin was 15.5% in the Jun 2026 quarter, 8.3 percentage points lower than the same quarter a year ago. Across 5 years it has been between −0.5% and 27.0%. The latest quarter is within that range.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −8.3 percentage points on the year while gross margin changed −0.8 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

FY25: 17.2%, within a range of −0.5% to 27.0% over 5 years

  • Operating margin 17.2%
FY25: 17.2%, within a range of −0.5% to 27.0% over 5 years
QuarterOperating margin
FY218.3%
FY22−0.5%
FY2324.9%
FY2427%
FY2517.2%

Change on the year before (points)

  • Change on the year before (points) −9.8 pts
Change on the year before (points)
QuarterChange on the year before (points)
FY21–
FY22−8.8 pts
FY23+25.4 pts
FY24+2.1 pts
FY25−9.8 pts
Operating margin each year, % (top). Below: change on the year before, in percentage points. 5-year window.

Jun 2026: operating margin 15.5% (−8.3 points on a year earlier)

  • Operating margin 15.5%
Jun 2026: operating margin 15.5% (−8.3 points on a year earlier)
QuarterOperating margin
Sep 202323.4%
Dec 202314.5%
Mar 202412.4%
Jun 202427.5%
Sep 202427.7%
Dec 202437.8%
Mar 20254.5%
Jun 202523.8%
Sep 202522.6%
Dec 202515.1%
Mar 2026−0.2%
Jun 202615.5%

Change on a year earlier (points)

  • Change on a year earlier (points) −8.3 pts
Change on a year earlier (points)
QuarterChange on a year earlier (points)
Sep 2023+47.4 pts
Dec 2023–
Mar 2024+16.2 pts
Jun 2024−18.1 pts
Sep 2024+4.3 pts
Dec 2024+23.3 pts
Mar 2025−7.9 pts
Jun 2025−3.7 pts
Sep 2025−5.1 pts
Dec 2025−22.7 pts
Mar 2026−4.7 pts
Jun 2026−8.3 pts
Top: quarterly operating margin, %. Below: change on the same quarter a year earlier, in percentage points. Last 12 quarters. Operating profit as a share of revenue, each quarter.

Is Alkermes' profit turning into cash?

Over the last 3 years, 141% of Alkermes plc's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $521 M of operating cash against $242 M of profit. After $40.4 M of spending on assets, $480 M was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

FY25: operating cash $521 M against profit $242 M; 141% of 3 years' profit came in as cash

  • Operating cash $521 M
  • Net profit $242 M
  • Free cash $480 M
FY25: operating cash $521 M against profit $242 M; 141% of 3 years' profit came in as cash
QuarterOperating cashNet profitFree cash
FY21$102 M−$48.2 M$73.7 M
FY22$21.0 M−$158 M−$17.2 M
FY23$401 M$356 M$353 M
FY24$439 M$367 M$406 M
FY25$521 M$242 M$480 M
Operating cash flow and net profit each year, $ M. The line is free cash flow: operating cash minus spending on assets. 5-year window, yearly figures.

Jun 2026: operating cash $145 M = 28,979% of the quarter's profit

  • Operating cash (quarterly) $145 M
Jun 2026: operating cash $145 M = 28,979% of the quarter's profit
QuarterOperating cash (quarterly)
Sep 2023$99.7 M
Dec 2023$107 M
Mar 2024$21.1 M
Jun 2024$146 M
Sep 2024$81.6 M
Dec 2024$190 M
Mar 2025$98.8 M
Jun 2025$150 M
Sep 2025$102 M
Dec 2025$170 M
Mar 2026−$166 M
Jun 2026$145 M

Operating cash as % of profit

  • Operating cash as % of profit 28,979%
Operating cash as % of profit
QuarterOperating cash as % of profit
Sep 2023209%
Dec 202395%
Mar 202457%
Jun 2024160%
Sep 202488%
Dec 2024130%
Mar 2025440%
Jun 2025172%
Sep 2025123%
Dec 2025345%
Mar 2026–
Jun 202628,979%
Top: operating cash each quarter, $ M. Below: operating cash as a % of net profit; 100% means all of the quarter's profit came in as cash. Last 12 quarters.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Where does Alkermes' cash go?

Alkermes plc does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $122 M on assets over the last 3 years. Averaged over those years that is 2.8% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $122 M over the last 3 years.

FY25: capex $40.4 M, steady spending

  • Capex $40.4 M
FY25: capex $40.4 M, steady spending
QuarterCapex
FY21$28.0 M
FY22$38.3 M
FY23$48.0 M
FY24$33.5 M
FY25$40.4 M
Capital spending each year, $ M.

Jun 2026: capex $8.1 M in the quarter

  • Capex (quarterly) $8.1 M
Jun 2026: capex $8.1 M in the quarter
QuarterCapex (quarterly)
Sep 2023$14.5 M
Dec 2023$17.0 M
Mar 2024$8.3 M
Jun 2024$7.1 M
Sep 2024$8.3 M
Dec 2024$9.8 M
Mar 2025$10.1 M
Jun 2025$13.0 M
Sep 2025$17.3 M
Dec 2025$0
Mar 2026$4.1 M
Jun 2026$8.1 M

Free cash

  • Free cash $137 M
Free cash
QuarterFree cash
Sep 2023$85.3 M
Dec 2023$90.2 M
Mar 2024$12.8 M
Jun 2024$139 M
Sep 2024$73.3 M
Dec 2024$181 M
Mar 2025$88.7 M
Jun 2025$137 M
Sep 2025$84.4 M
Dec 2025$170 M
Mar 2026−$170 M
Jun 2026$137 M
Top: capital spending each quarter, $ M. Below: free cash flow, $ M. Last 12 quarters.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

What is Alkermes' P/E ratio, and how does it compare with its own history?

Alkermes plc's P/E is 115.6×, near the high end of its own history: higher than 93% of past readings. Its usual P/E (the middle reading) is 15.6×, over 3.3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

P/E 115.6× against a usual 15.6×: near the high end of its own history: higher than 93% of past readings

  • P/E 46.9×
  • Median 15.6×
P/E 115.6× against a usual 15.6×: near the high end of its own history: higher than 93% of past readings
WeekP/EMedian
30 Jun 202346.9×15.6×
7 Jul 202346.9×15.6×
14 Jul 202346.9×15.6×
21 Jul 202346.9×15.6×
28 Jul 202346.9×15.6×
4 Aug 202346.9×15.6×
11 Aug 202346.9×15.6×
18 Aug 202346.9×15.6×
25 Aug 202346.9×15.6×
1 Sep 202346.9×15.6×
8 Sep 202346.9×15.6×
15 Sep 202346.9×15.6×
22 Sep 202346.9×15.6×
29 Sep 202346.9×15.6×
6 Oct 202328.2×15.6×
13 Oct 202327.3×15.6×
20 Oct 202326.6×15.6×
27 Oct 202323.5×15.6×
3 Nov 202324.4×15.6×
10 Nov 202323.4×15.6×
17 Nov 202323.8×15.6×
24 Nov 202324.0×15.6×
1 Dec 202323.9×15.6×
8 Dec 202325.4×15.6×
15 Dec 202327.0×15.6×
22 Dec 202327.4×15.6×
29 Dec 202327.3×15.6×
5 Jan 202413.8×15.6×
12 Jan 202413.6×15.6×
19 Jan 202413.5×15.6×
26 Jan 202413.4×15.6×
2 Feb 202412.9×15.6×
9 Feb 202413.2×15.6×
16 Feb 202415.6×15.6×
23 Feb 202414.3×15.6×
1 Mar 202414.6×15.6×
8 Mar 202414.1×15.6×
15 Mar 202413.9×15.6×
22 Mar 202413.2×15.6×
28 Mar 202413.1×15.6×
5 Apr 202410.3×15.6×
12 Apr 20249.62×15.6×
19 Apr 20249.39×15.6×
26 Apr 20249.72×15.6×
3 May 20249.47×15.6×
10 May 20249.47×15.6×
17 May 20249.51×15.6×
24 May 20249.46×15.6×
31 May 20249.22×15.6×
7 Jun 20249.42×15.6×
14 Jun 20249.65×15.6×
21 Jun 20249.83×15.6×
28 Jun 20249.49×15.6×
5 Jul 202414.4×15.6×
12 Jul 202414.0×15.6×
19 Jul 202414.7×15.6×
26 Jul 202416.6×15.6×
2 Aug 202416.4×15.6×
9 Aug 202415.5×15.6×
16 Aug 202416.2×15.6×
23 Aug 202416.6×15.6×
30 Aug 202416.9×15.6×
6 Sep 202415.9×15.6×
13 Sep 202416.4×15.6×
20 Sep 202416.9×15.6×
27 Sep 202416.3×15.6×
4 Oct 202414.7×15.6×
11 Oct 202414.7×15.6×
18 Oct 202414.4×15.6×
25 Oct 202413.3×15.6×
1 Nov 202413.5×15.6×
8 Nov 202414.7×15.6×
15 Nov 202414.3×15.6×
22 Nov 202414.6×15.6×
29 Nov 202414.8×15.6×
6 Dec 202416.0×15.6×
13 Dec 202415.5×15.6×
20 Dec 202415.1×15.6×
27 Dec 202415.0×15.6×
3 Jan 202513.3×15.6×
10 Jan 202512.8×15.6×
17 Jan 202513.5×15.6×
24 Jan 202514.3×15.6×
31 Jan 202514.4×15.6×
7 Feb 202514.4×15.6×
14 Feb 202516.4×15.6×
21 Feb 202516.2×15.6×
28 Feb 202515.7×15.6×
7 Mar 202515.7×15.6×
14 Mar 202515.6×15.6×
21 Mar 202515.8×15.6×
28 Mar 202515.2×15.6×
4 Apr 202514.3×15.6×
11 Apr 202512.9×15.6×
17 Apr 202512.9×15.6×
25 Apr 202513.3×15.6×
2 May 202515.1×15.6×
9 May 202514.3×15.6×
16 May 202515.0×15.6×
23 May 202514.0×15.6×
30 May 202514.6×15.6×
6 Jun 202515.1×15.6×
13 Jun 202514.2×15.6×
20 Jun 202513.9×15.6×
27 Jun 202513.7×15.6×
3 Jul 202513.8×15.6×
11 Jul 202514.5×15.6×
18 Jul 202514.0×15.6×
25 Jul 202512.5×15.6×
1 Aug 202512.7×15.6×
8 Aug 202512.8×15.6×
15 Aug 202513.9×15.6×
22 Aug 202514.3×15.6×
29 Aug 202513.9×15.6×
5 Sep 202514.3×15.6×
12 Sep 202512.9×15.6×
19 Sep 202513.3×15.6×
26 Sep 202513.4×15.6×
3 Oct 202515.4×15.6×
10 Oct 202515.4×15.6×
17 Oct 202515.0×15.6×
24 Oct 202514.8×15.6×
31 Oct 202515.2×15.6×
7 Nov 202516.3×15.6×
14 Nov 202514.4×15.6×
21 Nov 202514.2×15.6×
28 Nov 202514.6×15.6×
5 Dec 202514.6×15.6×
12 Dec 202514.1×15.6×
19 Dec 202514.1×15.6×
26 Dec 202514.1×15.6×
2 Jan 202619.8×15.6×
9 Jan 202620.7×15.6×
16 Jan 202622.1×15.6×
23 Jan 202623.5×15.6×
30 Jan 202623.7×15.6×
6 Feb 202624.4×15.6×
13 Feb 202623.2×15.6×
20 Feb 202622.3×15.6×
27 Feb 202621.0×15.6×
6 Mar 202620.0×15.6×
13 Mar 202619.4×15.6×
20 Mar 202619.7×15.6×
27 Mar 202620.5×15.6×
2 Apr 202638.7×15.6×
10 Apr 202637.0×15.6×
17 Apr 202638.3×15.6×
24 Apr 202637.0×15.6×
1 May 202637.0×15.6×
8 May 202638.8×15.6×
15 May 202641.6×15.6×
22 May 202640.8×15.6×
29 May 202646.8×15.6×
5 Jun 202646.9×15.6×
12 Jun 202646.9×15.6×
18 Jun 202646.9×15.6×
26 Jun 202646.9×15.6×
2 Jul 202646.9×15.6×
10 Jul 202646.9×15.6×
17 Jul 202646.9×15.6×
24 Jul 202646.9×15.6×
31 Jul 202646.9×15.6×
7 Aug 202646.9×15.6×
14 Aug 202646.9×15.6×
21 Aug 202646.9×15.6×
28 Aug 202646.9×15.6×
4 Sep 202646.9×15.6×
11 Sep 202646.9×15.6×
18 Sep 202646.9×15.6×
25 Sep 202646.9×15.6×
2 Oct 202646.9×15.6×
9 Oct 202646.9×15.6×
16 Oct 202646.9×15.6×
23 Oct 202646.9×15.6×
30 Oct 202646.9×15.6×
4 Nov 202646.9×15.6×

Earnings per share, 12 months

  • Earnings per share, 12 months $0.38
Earnings per share, 12 months
WeekEarnings per share, 12 months
30 Jun 2023$0.56
7 Jul 2023$0.56
14 Jul 2023$0.56
21 Jul 2023$0.56
28 Jul 2023$0.56
4 Aug 2023$0.56
11 Aug 2023$0.56
18 Aug 2023$0.56
25 Aug 2023$0.56
1 Sep 2023$0.56
8 Sep 2023$0.56
15 Sep 2023$0.56
22 Sep 2023$0.56
29 Sep 2023$0.56
6 Oct 2023$0.56
13 Oct 2023$0.56
20 Oct 2023$0.56
27 Oct 2023$0.56
3 Nov 2023$0.56
10 Nov 2023$0.56
17 Nov 2023$0.56
24 Nov 2023$0.56
1 Dec 2023$0.56
8 Dec 2023$0.56
15 Dec 2023$0.56
22 Dec 2023$0.56
29 Dec 2023$1.02
5 Jan 2024$1.02
12 Jan 2024$1.02
19 Jan 2024$1.02
26 Jan 2024$1.02
2 Feb 2024$1.02
9 Feb 2024$1.02
16 Feb 2024$1.02
23 Feb 2024$1.02
1 Mar 2024$1.02
8 Mar 2024$1.02
15 Mar 2024$1.02
22 Mar 2024$1.02
28 Mar 2024$2.07
5 Apr 2024$2.07
12 Apr 2024$2.07
19 Apr 2024$2.07
26 Apr 2024$2.07
3 May 2024$2.07
10 May 2024$2.07
17 May 2024$2.07
24 May 2024$2.07
31 May 2024$2.07
7 Jun 2024$2.07
14 Jun 2024$2.07
21 Jun 2024$2.07
28 Jun 2024$2.54
5 Jul 2024$2.54
12 Jul 2024$2.54
19 Jul 2024$2.54
26 Jul 2024$2.54
2 Aug 2024$2.54
9 Aug 2024$2.54
16 Aug 2024$2.54
23 Aug 2024$2.54
30 Aug 2024$2.54
6 Sep 2024$2.54
13 Sep 2024$2.54
20 Sep 2024$2.54
27 Sep 2024$1.69
4 Oct 2024$1.69
11 Oct 2024$1.69
18 Oct 2024$1.69
25 Oct 2024$1.69
1 Nov 2024$1.69
8 Nov 2024$1.69
15 Nov 2024$1.69
22 Nov 2024$1.69
29 Nov 2024$1.69
6 Dec 2024$1.69
13 Dec 2024$1.69
20 Dec 2024$1.69
27 Dec 2024$1.97
3 Jan 2025$1.97
10 Jan 2025$1.97
17 Jan 2025$1.97
24 Jan 2025$1.97
31 Jan 2025$1.97
7 Feb 2025$1.97
14 Feb 2025$1.97
21 Feb 2025$1.97
28 Feb 2025$1.97
7 Mar 2025$1.97
14 Mar 2025$1.97
21 Mar 2025$1.97
28 Mar 2025$2.19
4 Apr 2025$2.19
11 Apr 2025$2.19
17 Apr 2025$2.19
25 Apr 2025$2.19
2 May 2025$2.19
9 May 2025$2.19
16 May 2025$2.19
23 May 2025$2.19
30 May 2025$2.19
6 Jun 2025$2.19
13 Jun 2025$2.19
20 Jun 2025$2.19
27 Jun 2025$2.10
3 Jul 2025$2.10
11 Jul 2025$2.10
18 Jul 2025$2.10
25 Jul 2025$2.10
1 Aug 2025$2.10
8 Aug 2025$2.10
15 Aug 2025$2.10
22 Aug 2025$2.10
29 Aug 2025$2.10
5 Sep 2025$2.10
12 Sep 2025$2.10
19 Sep 2025$2.10
26 Sep 2025$2.09
3 Oct 2025$2.09
10 Oct 2025$2.09
17 Oct 2025$2.09
24 Oct 2025$2.09
31 Oct 2025$2.09
7 Nov 2025$2.09
14 Nov 2025$2.09
21 Nov 2025$2.09
28 Nov 2025$2.09
5 Dec 2025$2.09
12 Dec 2025$2.09
19 Dec 2025$2.09
26 Dec 2025$2.02
2 Jan 2026$2.02
9 Jan 2026$2.02
16 Jan 2026$2.02
23 Jan 2026$2.02
30 Jan 2026$2.02
6 Feb 2026$2.02
13 Feb 2026$2.02
20 Feb 2026$2.02
27 Feb 2026$2.02
6 Mar 2026$2.02
13 Mar 2026$2.02
20 Mar 2026$2.02
27 Mar 2026$1.43
2 Apr 2026$1.43
10 Apr 2026$1.43
17 Apr 2026$1.43
24 Apr 2026$1.43
1 May 2026$1.43
8 May 2026$1.43
15 May 2026$1.43
22 May 2026$1.43
29 May 2026$1.43
5 Jun 2026$1.43
12 Jun 2026$1.43
18 Jun 2026$1.43
26 Jun 2026$0.90
2 Jul 2026$0.90
10 Jul 2026$0.90
17 Jul 2026$0.90
24 Jul 2026$0.90
31 Jul 2026$0.90
7 Aug 2026$0.90
14 Aug 2026$0.90
21 Aug 2026$0.90
28 Aug 2026$0.90
4 Sep 2026$0.90
11 Sep 2026$0.90
18 Sep 2026$0.90
25 Sep 2026$0.38
2 Oct 2026$0.38
9 Oct 2026$0.38
16 Oct 2026$0.38
23 Oct 2026$0.38
30 Oct 2026$0.38
4 Nov 2026$0.38
Top: P/E each week. Below: earnings per share, trailing twelve months, a step line that moves once a quarter; 3.3 years of history; short peaks above 47× are drawn at the top edge.

PEG 1.75 at the Jun 2026 quarter end: above 1.0, so the P/E is bigger than the earnings growth rate

  • PEG 1.75×
  • PEG = 1.0 1.00×
PEG 1.75 at the Jun 2026 quarter end: above 1.0, so the P/E is bigger than the earnings growth rate
QuarterPEGPEG = 1.0
Dec 20216.00×1.00×
Mar 20226.00×1.00×
Jun 20226.00×1.00×
Sep 20226.00×1.00×
Dec 20226.00×1.00×
Jun 20230.35×1.00×
Sep 20230.28×1.00×
Dec 20230.14×1.00×
Mar 20240.27×1.00×
Jun 20240.41×1.00×
Sep 20240.52×1.00×
Dec 20241.05×1.00×
Mar 20251.75×1.00×
Jun 20251.75×1.00×
Sep 20251.75×1.00×
Dec 20251.75×1.00×
Mar 20261.75×1.00×
Jun 20261.75×1.00×
PEG each quarter: the P/E divided by the yearly growth rate of earnings. The flat line marks 1.0. Below it the P/E is smaller than the growth rate; above it the P/E is bigger. Last 18 quarters; values above 6 are drawn at the top edge.
115.6×P/E · higher than 93% of its last 3.3 years
24.19PEG · today, derived from 3-year earnings growth

Why the multiple is where it is: over the past year earnings per share moved −34.1% while the price moved +39.5%. The price did better than earnings, which pushed the multiple up within its own range.

Where the price move came from: over 3 years the price moved +22.8% a year; about −27.7% a year came from earnings growth and about +50.5 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

Is the Alkermes business getting better or worse?

Alkermes plc's business is getting worse. Profit and EPS growth are shrinking: profit growth is −81.0% in the latest quarter, against +185.6% at its best in 12 quarters, with ROCE falling at 8.2%. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Growth year by year: revenue −5.2% in FY25, profit −34.2%

  • Revenue growth −5.2%
Growth year by year: revenue −5.2% in FY25, profit −34.2%
QuarterRevenue growth
FY21–
FY22−5.3%
FY2349.6%
FY24−6.4%
FY25−5.2%

Profit growth, EPS growth

  • Profit growth −34.2%
  • EPS growth −34.1%
Profit growth, EPS growth
QuarterProfit growthEPS growth
FY21––
FY22––
FY23––
FY243.2%3.5%
FY25−34.2%−34.1%
Growth on the year before, each year, %. Top: revenue. Below: net profit and earnings per share, on their own scale because profit growth swings much more. Zero line drawn.

Three growth lines over twelve quarters: revenue accelerating, profit rolling over

  • Revenue 10.8%
Three growth lines over twelve quarters: revenue accelerating, profit rolling over
QuarterRevenue
Sep 202331.1%
Dec 202347%
Mar 202457.7%
Jun 20245.2%
Sep 2024−2.2%
Dec 2024−6.4%
Mar 2025−12.3%
Jun 2025−0.2%
Sep 20251.1%
Dec 2025−5.2%
Mar 20263.2%
Jun 202610.8%

Profit, EPS

  • Profit −81%
  • EPS −81.6%
Profit, EPS
QuarterProfitEPS
Sep 2023––
Dec 2023––
Mar 2024––
Jun 2024185.6%202.2%
Sep 202486.2%93.5%
Dec 20243.2%5.7%
Mar 2025−18.8%−17.4%
Jun 202520.7%23.9%
Sep 20251.6%2.7%
Dec 2025−34.2%−34.6%
Mar 2026−56.7%−57.1%
Jun 2026−81%−81.6%
Growth on a year earlier, % at each quarter end. Top: revenue. Below: profit and earnings per share, on their own scale because they swing much more. Each is measured over the last 12 months. A gap means there is no reading for that quarter.

ROCE: the return line, worked out each quarter

  • ROCE 8.2%
ROCE: the return line, worked out each quarter
QuarterROCE
Sep 202318.1%
Dec 202326.8%
Mar 202430.3%
Jun 202417.5%
Sep 202418%
Dec 202426.2%
Mar 202523.7%
Jun 202521.8%
Sep 202520.2%
Dec 202514.4%
Mar 20269%
Jun 20268.2%
Operating profit over the last 12 months (before interest and tax) as a share of average capital employed (total assets minus current liabilities), %.
RisingRevenue growth · latest +10.8%, range −12.3% to +57.7%
FallingProfit growth · latest −81.0%, range −81.0% to +185.6%
FallingEPS growth · latest −81.6%, range −81.6% to +202.2%
FallingROCE · latest 8.2%, range 8.2% to 30.3%

Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Compound annual growth rate (%)
Measure1yr3yr5yr10yr
Revenue−5.2%+9.9%——
Profit−34.2%———
EPS−34.1%———
Stock price+39.5%+22.8%+8.6%−1.2%
+27.0%Revenue growth (Jun 2026) · latest quarter against a year ago
−99.4%Profit growth (Jun 2026) · latest quarter against a year ago
5.9%Revenue, 4 years · yearly growth over the long run

How much does Alkermes earn on its capital?

Alkermes plc earned a ROE of 13% in FY25. That is up from a low of −15% in FY22. Its return on capital used (ROIC) is 4.9 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses.

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

It comes from a 16.4% net margin and 0.59× asset turnover (sales divided by assets).

Why the return is what it is (FY25): a 16.4% net margin × 0.59× asset turnover × 1.37× leverage (assets divided by equity) ≈ 13.3% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: −0.3% − 4.6% = −4.9 percentage points. The 4.6% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

The −0.3% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 20.2%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

FY25: ROE 13%, the climb back from FY22's −15%

  • ROE 13.3%
  • ROIC (annual) 20.2%
  • Cost of capital 4.6%
FY25: ROE 13%, the climb back from FY22's −15%
QuarterROEROIC (annual)Cost of capital
FY21−4.3%9.3%4.6%
FY22−15.2%−0.7%4.6%
FY2329.6%51.2%4.6%
FY2425.1%44.4%4.6%
FY2513.3%20.2%4.6%
Return on equity each year, % (line); ROIC each year, % (line). 5-year window, low years included. The flat line is the 4.6% cost of capital used on this page.

Jun 2026: ROIC 26.6% (last 12 months) against a 4.6% cost of capital

  • ROIC (12 months) 26.6%
  • ROE (12 months) 38.1%
  • Cost of capital 4.6%
Jun 2026: ROIC 26.6% (last 12 months) against a 4.6% cost of capital
QuarterROIC (12 months)ROE (12 months)Cost of capital
Sep 202322.1%57.7%4.6%
Dec 202336.2%96.7%4.6%
Mar 202449.6%171%4.6%
Jun 202455.3%188.4%4.6%
Sep 202432.1%120.5%4.6%
Dec 202433.3%121.5%4.6%
Mar 202544.8%113.6%4.6%
Jun 202542.1%106.9%4.6%
Sep 202542.5%99.3%4.6%
Dec 202541.5%90.2%4.6%
Mar 202628.2%59%4.6%
Jun 202626.6%38.1%4.6%
ROIC and ROE over the last 12 months, each quarter, %; the flat line is the cost of capital. Last 12 quarters, lined up with the yearly figure.

Does Alkermes have too much debt?

Alkermes plc has total debt of $1.6 B against shareholder equity of $1.8 B as of Jun 2026, so its debt is 0.87× its equity. Year by year, that ratio went from 0.37 in FY21 to 0.04 in FY25. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

FY25: debt $70.0 M, 0.04× equity

  • Total debt $70.0 M
FY25: debt $70.0 M, 0.04× equity
QuarterTotal debt
FY21$416 M
FY22$379 M
FY23$372 M
FY24$75.5 M
FY25$70.0 M

Debt-to-equity

  • Debt-to-equity 0.04×
Debt-to-equity
QuarterDebt-to-equity
FY210.37×
FY220.36×
FY230.31×
FY240.05×
FY250.04×
Top: total debt each year, $ M. Below: debt-to-equity, ×. 5-year window.

Jun 2026: debt $1.6 B, debt-to-equity 0.87

  • Total debt (quarterly) $1.6 B
Jun 2026: debt $1.6 B, debt-to-equity 0.87
QuarterTotal debt (quarterly)
Sep 2023$385 M
Dec 2023$372 M
Mar 2024$370 M
Jun 2024$368 M
Sep 2024$366 M
Dec 2024$75.5 M
Mar 2025$74.1 M
Jun 2025$72.7 M
Sep 2025$71.6 M
Dec 2025$70.0 M
Mar 2026$1.6 B
Jun 2026$1.6 B

Debt-to-equity

  • Debt-to-equity 0.87×
Debt-to-equity
QuarterDebt-to-equity
Sep 20230.28×
Dec 20230.31×
Mar 20240.29×
Jun 20240.29×
Sep 20240.28×
Dec 20240.05×
Mar 20250.05×
Jun 20250.04×
Sep 20250.04×
Dec 20250.04×
Mar 20260.90×
Jun 20260.87×
Top: total debt each quarter, $ B. Below: debt-to-equity, ×. Last 12 quarters.

What is the Alkermes shareholding pattern?

12.3% of Alkermes plc's tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 7.7 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

12.3%Short interest · of the tradable float
7.7Days to cover · at typical volumes

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

How far is Alkermes from balance-sheet trouble?

For Alkermes plc, the Z-score is 1.76. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 1.76 is inside the danger zone, so the balance sheet is a real risk.

How does Alkermes rank in its industry?

43.6 out of 100, rank 21 of 28 in Drug Manufacturers - Specialty & Generic, with 81% of the evidence available.

Alkermes plc scores 43.6 out of 100 against the 28 companies it is compared with in Drug Manufacturers - Specialty & Generic, ranking 21. The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far.

The four parts add up to the total exactly: 10 + 10.4 + 13.5 + 9.7 = 43.6. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Which companies is Alkermes compared with?

Alkermes ranks 21 of 28 Drug Manufacturers - Specialty & Generic companies on the 4-Factor Sector Score, with 43.6 out of 100.

  1. 1Neurocrine Biosciences, Inc.NBIX · turning · Most evidence points up · 81% evidence66.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 26.1/35 · Revenue 34.4% · Profit 100% · Operating margin change 1 points · 83% evidenceCapital efficiency 18.2/25 · ROCE 19.3% · Operating margin 22.2% · 76% evidenceValuation 13.8/20 · P/E 24× · PEG 0.71 · 65% evidenceRelative strength 8.2/20 · Lead over its industry -5.3% · Lead over S&P 500 6.1% · 1 year 9% · 100% evidence · 0 of 12 weeks aheadExact sum: 26.1 + 18.2 + 13.8 + 8.2 = 66.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  2. 2Indivior Pharmaceuticals, Inc.INDV · quiet · Evidence leans up · 71% evidence63.2out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 27.8/35 · Revenue 13.5% · Profit 100% · Operating margin change 23.4 points · 83% evidenceCapital efficiency 20.8/25 · ROCE 152.3% · Operating margin 46.9% · 76% evidenceValuation 10.3/20 · P/E 14.1× · PEG — · 15% evidenceRelative strength 4.3/20 · Lead over its industry -13.9% · Lead over S&P 500 -3.7% · 1 year 15.8% · 100% evidence · 0 of 12 weeks aheadExact sum: 27.8 + 20.8 + 10.3 + 4.3 = 63.2 · What this means: Earnings are strong; relative strength in its sector is -13.9% and the one-year return is 15.8%.
  3. 3Kiniksa Pharmaceuticals International, plcKNSA · leader · Evidence leans up · 71% evidence62.1out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 24.1/35 · Revenue 58.7% · Profit 100% · Operating margin change -1.7 points · 83% evidenceCapital efficiency 12.2/25 · ROCE 13.8% · Operating margin 11.2% · 76% evidenceValuation 9.0/20 · P/E 61× · PEG — · 15% evidenceRelative strength 16.8/20 · Lead over its industry 43.2% · Lead over S&P 500 59% · 1 year 150.5% · 100% evidence · 12 of 12 weeks aheadExact sum: 24.1 + 12.2 + 9 + 16.8 = 62.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  4. 4Bausch Health Companies Inc.BHC · leader · Evidence leans up · 71% evidence60.1out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 17.9/35 · Revenue 10.1% · Profit -1220.4% · Operating margin change 9.1 points · 83% evidenceCapital efficiency 12.8/25 · ROCE 13.5% · Operating margin 27.2% · 76% evidenceValuation 10.9/20 · P/E -1.7× · PEG — · 15% evidenceRelative strength 18.5/20 · Lead over its industry 17.1% · Lead over S&P 500 30.9% · 1 year 25.4% · 100% evidence · 12 of 12 weeks aheadExact sum: 17.9 + 12.8 + 10.9 + 18.5 = 60.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  5. 5Xeris Biopharma Holdings, Inc.XERS · leader · Evidence leans up · 64% evidence60.0out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 21.1/35 · Revenue 36.2% · Profit — · Operating margin change -0.7 points · 62% evidenceCapital efficiency 11.8/25 · ROCE 16.5% · Operating margin 5.6% · 76% evidenceValuation 8.7/20 · P/E 83.3× · PEG — · 15% evidenceRelative strength 18.4/20 · Lead over its industry 18.3% · Lead over S&P 500 31.8% · 1 year 40.8% · 100% evidence · 12 of 12 weeks aheadExact sum: 21.1 + 11.8 + 8.7 + 18.4 = 60 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  6. 6Phibro Animal Health CorporationPAHC · breaking out · Evidence leans up · 81% evidence58.6out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 24.4/35 · Revenue 17.2% · Profit 100% · Operating margin change 0.3 points · 83% evidenceCapital efficiency 15.3/25 · ROCE 16.4% · Operating margin 10.6% · 76% evidenceValuation 11.8/20 · P/E 12.8× · PEG 1.44 · 65% evidenceRelative strength 7.1/20 · Lead over its industry -19.8% · Lead over S&P 500 -10.4% · 1 year -9.9% · 100% evidence · 11 of 12 weeks aheadExact sum: 24.4 + 15.3 + 11.8 + 7.1 = 58.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  7. 7Amneal Pharmaceuticals, Inc.AMRX · leader · Evidence leans up · 71% evidence58.6out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 21.4/35 · Revenue 9.3% · Profit 100% · Operating margin change 2.8 points · 83% evidenceCapital efficiency 15.1/25 · ROCE 17.1% · Operating margin 18.3% · 76% evidenceValuation 9.3/20 · P/E 35.1× · PEG — · 15% evidenceRelative strength 12.8/20 · Lead over its industry 11.3% · Lead over S&P 500 23.9% · 1 year 75.5% · 100% evidence · 10 of 12 weeks aheadExact sum: 21.4 + 15.1 + 9.3 + 12.8 = 58.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  8. 8BioCryst Pharmaceuticals, Inc.BCRX · quiet · Evidence leans up · 64% evidence58.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 25.6/35 · Revenue 68.5% · Profit — · Operating margin change 26.9 points · 62% evidenceCapital efficiency 18.1/25 · ROCE 112% · Operating margin 45.1% · 76% evidenceValuation 11.0/20 · P/E -6.6× · PEG — · 15% evidenceRelative strength 3.6/20 · Lead over its industry -18% · Lead over S&P 500 -8.4% · 1 year 16.2% · 100% evidence · 3 of 12 weeks aheadExact sum: 25.6 + 18.1 + 11 + 3.6 = 58.3 · What this means: Earnings are strong; relative strength in its sector is -18% and the one-year return is 16.2%.
  9. 9Liquidia CorporationLQDA · quiet · Evidence leans up · 64% evidence55.8out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 26.0/35 · Revenue 100% · Profit — · Operating margin change 474.2 points · 62% evidenceCapital efficiency 17.9/25 · ROCE 50.7% · Operating margin 49.8% · 76% evidenceValuation 9.2/20 · P/E 51.2× · PEG — · 15% evidenceRelative strength 2.7/20 · Lead over its industry -19.6% · Lead over S&P 500 -10.2% · 1 year 81.6% · 100% evidence · 3 of 12 weeks aheadExact sum: 26 + 17.9 + 9.2 + 2.7 = 55.8 · What this means: Earnings are strong; relative strength in its sector is -19.6% and the one-year return is 81.6%.
  10. 10United Therapeutics CorporationUTHR · turning · Evidence leans up · 81% evidence55.4out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 14.5/35 · Revenue 2.5% · Profit 5.6% · Operating margin change -6.2 points · 83% evidenceCapital efficiency 20.3/25 · ROCE 21.2% · Operating margin 42.2% · 76% evidenceValuation 9.2/20 · P/E 17.5× · PEG 1.92 · 65% evidenceRelative strength 11.4/20 · Lead over its industry -2.5% · Lead over S&P 500 8.9% · 1 year 35.5% · 100% evidence · 3 of 12 weeks aheadExact sum: 14.5 + 20.3 + 9.2 + 11.4 = 55.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  11. 11Viatris Inc.VTRS · breaking out · Evidence leans up · 64% evidence52.4out of 100GrowthCapitalValuationRelative
  12. 12Trulieve Cannabis Corp.TRLV · breaking out · Evidence leans up · 64% evidence50.8out of 100GrowthCapitalValuationRelative
  13. 13Pacira BioSciences, Inc.PCRX · breaking out · Evidence leans up · 64% evidence50.3out of 100GrowthCapitalValuationRelative
  14. 14ANI Pharmaceuticals, Inc.ANIP · basing · Evidence leans down · 64% evidence48.3out of 100GrowthCapitalValuationRelative
  15. 15Zoetis Inc.ZTS · turning · Evidence leans down · 81% evidence47.1out of 100GrowthCapitalValuationRelative
  16. 16Teva Pharmaceutical Industries LimitedTEVA · leader · Evidence leans down · 64% evidence46.9out of 100GrowthCapitalValuationRelative
  17. 17Haleon plcHLN · basing · Too little evidence to rank firmly · 56% evidence46.2out of 100GrowthCapitalValuationRelative
  18. 18Perrigo Company plcPRGO · breaking out · Evidence leans down · 64% evidence45.1out of 100GrowthCapitalValuationRelative
  19. 19Elanco Animal Health IncorporatedELAN · turning · Evidence leans down · 71% evidence44.9out of 100GrowthCapitalValuationRelative
  20. 20Lantheus Holdings, Inc.LNTH · turning · Evidence leans down · 81% evidence43.8out of 100GrowthCapitalValuationRelative
  21. 21Alkermes plc this pageALKS · quiet · Evidence leans down · 81% evidence43.6out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 10.0/35 · Revenue 10.8% · Profit -80.8% · Operating margin change -8.3 points · 83% evidenceCapital efficiency 10.4/25 · ROCE 6% · Operating margin 15.5% · 76% evidenceValuation 13.5/20 · P/E 132.1× · PEG 0.57 · 65% evidenceRelative strength 9.7/20 · Lead over its industry 1.2% · Lead over S&P 500 12.8% · 1 year 39.5% · 100% evidence · 2 of 12 weeks aheadExact sum: 10 + 10.4 + 13.5 + 9.7 = 43.6 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far.
  22. 22HUTCHMED (China) LimitedHCM · breaking out · Too little evidence to rank firmly · 51% evidence40.8out of 100GrowthCapitalValuationRelative
  23. 23Prestige Consumer Healthcare Inc.PBH · basing · Evidence leans down · 71% evidence37.8out of 100GrowthCapitalValuationRelative
  24. 24AlvotechALVO · breaking out · Most evidence points down · 71% evidence33.7out of 100GrowthCapitalValuationRelative
  25. 25Hims & Hers Health, Inc.HIMS · quiet · Most evidence points down · 71% evidence27.4out of 100GrowthCapitalValuationRelative
  26. 26Supernus Pharmaceuticals, Inc.SUPN · quiet · Most evidence points down · 71% evidence26.6out of 100GrowthCapitalValuationRelative
  27. 27Amylyx Pharmaceuticals, Inc.AMLX · leader · Too little evidence to rank firmly · 40% evidence47.7out of 100GrowthCapitalValuationRelative
  28. 28Regencell Bioscience Holdings LimitedRGC · losing its lead · Too little evidence to rank firmly · 47% evidence30.6out of 100GrowthCapitalValuationRelative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Drug Manufacturers - Specialty & Generic, all 28 compared on one page.

Which companies are close to Alkermes in size?

Alkermes is the 10th largest of 51 Drug Manufacturers - Specialty & Generic companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Neurocrine Biosciences, Inc., Elanco Animal Health Incorporated and Dr. Reddy's Laboratories. Just below it: Kiniksa Pharmaceuticals International, plc, Amneal Pharmaceuticals, Inc. and Lantheus Holdings, Inc.

Drug Manufacturers - Specialty & Generic companies close in size

  1. Neurocrine Biosciences, Inc. $16.8 billion
  2. Elanco Animal Health Incorporated $12.6 billion
  3. Dr. Reddy's Laboratories Limited $12.1 billion
  4. Alkermes plc $7.7 billion
  5. Kiniksa Pharmaceuticals International, plc $7.6 billion
  6. Amneal Pharmaceuticals, Inc. $6.9 billion
  7. Lantheus Holdings, Inc. $6.6 billion

All 51 Drug Manufacturers - Specialty & Generic companies, largest first

Companies close in size in other industries

  1. Eastman Chemical Company $7.7 billion · Specialty Chemicals
  2. Sanmina Corporation $7.7 billion · Electronic Components
  3. Alkermes plc $7.7 billion
  4. XP Inc. $7.7 billion · Capital Markets
  5. SPX Technologies, Inc. $7.7 billion · Building Products & Equipment

What else do people ask about Alkermes?

What were Alkermes's latest quarterly results?

Alkermes plc reported revenue of $496 M and net profit of $501 K for the Jun 2026 quarter. Revenue rose 27.0% and profit fell 99.4% compared with a year earlier. Earnings per share were $0.00.

The operating margin was 15.5%, 8.3 percentage points lower than a year earlier (as of 4 November 2026).

What is Alkermes's market cap?

Alkermes plc's market capitalisation is $7.7 B at a stock price of $45.89. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026).

How is Alkermes performing?

Alkermes plc's share price has been rising for 26 weeks. In its latest quarter, revenue rose 27.0% and profit fell 99.4% compared with a year earlier. Over the past 13 weeks it has done worse than the S&P 500, for 8 weeks running (as of 4 November 2026).

Will Alkermes's stock price go up?

This page does not forecast Alkermes plc's stock price. What it shows instead: the stock price is $45.89, and it has been rising for 26 weeks. Its P/E of 115.6× is higher than 93% of its own last 3 years (as of 4 November 2026).

Does Alkermes have too much debt?

Alkermes plc has a moderate amount of debt: its debt is 0.80× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. Keep that borrowing in mind when reading the returns on this page (as of 4 November 2026).

Where is Alkermes in its business cycle?

Alkermes plc's FY25 operating margin was 17.2%, against a 5-year range of −0.5% to 27.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 15.5%.

Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026).

What could break the Alkermes story?

The main question: the share price moved +39.5% in a year while yearly earnings per share moved −34.1%. The difference came from the market paying a higher multiple.

On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026).

Is Alkermes a stock worth studying right now?

What the numbers show: Alkermes plc's share price has risen faster than its earnings: +39.5% in a year, against −34.1% for earnings per share. The main open question: whether earnings grow into a price that has already moved.

Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026).

Where do these numbers come from?

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.

More lists

Every Sector Alpha list, grouped

X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.